BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20305816)

  • 21. Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies.
    Hoffmann MJ; Müller M; Engers R; Schulz WA
    Biochem Pharmacol; 2006 Nov; 72(11):1577-88. PubMed ID: 16854382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
    Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
    Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible prognostic value of BORIS transcript variants ratio in laryngeal squamous cell carcinomas - a pilot study.
    Novak Kujundžić R; Grbeša I; Ivkić M; Krušlin B; Konjevoda P; Gall Trošelj K
    Pathol Oncol Res; 2014 Jul; 20(3):687-95. PubMed ID: 24563233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting CTCFL/BORIS for the immunotherapy of cancer.
    Loukinov D
    Cancer Immunol Immunother; 2018 Dec; 67(12):1955-1965. PubMed ID: 30390146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells.
    Tiffen JC; Bailey CG; Marshall AD; Metierre C; Feng Y; Wang Q; Watson SL; Holst J; Rasko JE
    Int J Cancer; 2013 Oct; 133(7):1603-13. PubMed ID: 23553099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
    Alberti L; Losi L; Leyvraz S; Benhattar J
    PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Hillman JC; Pugacheva EM; Barger CJ; Sribenja S; Rosario S; Albahrani M; Truskinovsky AM; Stablewski A; Liu S; Loukinov DI; Zentner GE; Lobanenkov VV; Karpf AR; Higgins MJ
    Mol Cancer Res; 2019 Oct; 17(10):2051-2062. PubMed ID: 31292201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The combined action of CTCF and its testis-specific paralog BORIS is essential for spermatogenesis.
    Rivero-Hinojosa S; Pugacheva EM; Kang S; Méndez-Catalá CF; Kovalchuk AL; Strunnikov AV; Loukinov D; Lee JT; Lobanenkov VV
    Nat Commun; 2021 Jun; 12(1):3846. PubMed ID: 34158481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BORIS/CTCFL-mediated transcriptional regulation of the hTERT telomerase gene in testicular and ovarian tumor cells.
    Renaud S; Loukinov D; Alberti L; Vostrov A; Kwon YW; Bosman FT; Lobanenkov V; Benhattar J
    Nucleic Acids Res; 2011 Feb; 39(3):862-73. PubMed ID: 20876690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma.
    Loukinov DI; Pugacheva E; Vatolin S; Pack SD; Moon H; Chernukhin I; Mannan P; Larsson E; Kanduri C; Vostrov AA; Cui H; Niemitz EL; Rasko JE; Docquier FM; Kistler M; Breen JJ; Zhuang Z; Quitschke WW; Renkawitz R; Klenova EM; Feinberg AP; Ohlsson R; Morse HC; Lobanenkov VV
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6806-11. PubMed ID: 12011441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testis-specific transcriptional regulators selectively occupy BORIS-bound CTCF target regions in mouse male germ cells.
    Rivero-Hinojosa S; Kang S; Lobanenkov VV; Zentner GE
    Sci Rep; 2017 Feb; 7():41279. PubMed ID: 28145452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions.
    Pugacheva EM; Rivero-Hinojosa S; Espinoza CA; Méndez-Catalá CF; Kang S; Suzuki T; Kosaka-Suzuki N; Robinson S; Nagarajan V; Ye Z; Boukaba A; Rasko JE; Strunnikov AV; Loukinov D; Ren B; Lobanenkov VV
    Genome Biol; 2015 Aug; 16(1):161. PubMed ID: 26268681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BORIS/CTCFL epigenetically reprograms clustered CTCF binding sites into alternative transcriptional start sites.
    Pugacheva EM; Bhatt DN; Rivero-Hinojosa S; Tajmul M; Fedida L; Price E; Ji Y; Loukinov D; Strunnikov AV; Ren B; Lobanenkov VV
    Genome Biol; 2024 Jan; 25(1):40. PubMed ID: 38297316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High expression of hTERT and stemness genes in BORIS/CTCFL positive cells isolated from embryonic cancer cells.
    Alberti L; Renaud S; Losi L; Leyvraz S; Benhattar J
    PLoS One; 2014; 9(10):e109921. PubMed ID: 25279549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.
    Kholmanskikh O; Loriot A; Brasseur F; De Plaen E; De Smet C
    Int J Cancer; 2008 Feb; 122(4):777-84. PubMed ID: 17957795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells.
    Gagnon J; Shaker S; Primeau M; Hurtubise A; Momparler RL
    Anticancer Drugs; 2003 Mar; 14(3):193-202. PubMed ID: 12634613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BORIS and CTCF are overexpressed in squamous intraepithelial lesions and cervical cancer.
    Velázquez-Hernández N; Reyes-Romero MA; Barragán-Hernández M; Guerrero-Romero F; Rodríguez-Moran M; Aguilar-Durán M; Lazalde Medina B
    Genet Mol Res; 2015 Jun; 14(2):6094-100. PubMed ID: 26125810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel mechanism for CTCF in the epigenetic regulation of Bax in breast cancer cells.
    Méndez-Catalá CF; Gretton S; Vostrov A; Pugacheva E; Farrar D; Ito Y; Docquier F; Kita GX; Murrell A; Lobanenkov V; Klenova E
    Neoplasia; 2013 Aug; 15(8):898-912. PubMed ID: 23908591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.
    Kastl L; Brown I; Schofield AC
    Int J Oncol; 2010 May; 36(5):1235-41. PubMed ID: 20372798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.
    Debruyne DN; Dries R; Sengupta S; Seruggia D; Gao Y; Sharma B; Huang H; Moreau L; McLane M; Day DS; Marco E; Chen T; Gray NS; Wong KK; Orkin SH; Yuan GC; Young RA; George RE
    Nature; 2019 Aug; 572(7771):676-680. PubMed ID: 31391581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.